SONN - Sonnet BioTherapeutics Holdings, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Princeton,
United States
Type: Equity
SONN price evolution
SONN
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $0.15 | $3.55 | $3.79 | $3.02 |
| Short term investments | ||||
| Net receivables | $0.76 | $0.52 | $0.38 | $0.19 |
| Inventory | ||||
| Total current assets | $2.12 | $5.13 | $5.22 | $4.62 |
| Long term investments | ||||
| Property, plant & equipment | $0.14 | $0.17 | $0.19 | $0.21 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.67 | $0.69 | $0.71 | |
| Total investments | ||||
| Total assets | $2.77 | $5.8 | $5.91 | $5.34 |
| Current liabilities | ||||
| Accounts payable | $2.18 | $1.88 | $1.75 | $1.66 |
| Deferred revenue | ||||
| Short long term debt | $0.08 | $0.08 | $0.08 | |
| Total current liabilities | $3.21 | $3.11 | $2.76 | $2.65 |
| Long term debt | $0.07 | $0.09 | $0.11 | |
| Total noncurrent liabilities | $0.07 | $0.09 | $0.11 | |
| Total debt | $0.15 | $0.17 | $0.19 | |
| Total liabilities | $3.26 | $3.18 | $2.86 | $2.77 |
| Shareholders' equity | ||||
| Retained earnings | -$117.68 | -$114.55 | -$111.05 | -$111.41 |
| Other shareholder equity | ||||
| Total shareholder equity | $2.62 | $3.05 | $2.57 | |
| (in millions $) | 30 Oct 2024 | 31 Dec 2023 | 30 Oct 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $0.15 | $2.27 | $3.05 | $27.62 |
| Short term investments | ||||
| Net receivables | $0.76 | $0.79 | ||
| Inventory | ||||
| Total current assets | $2.12 | $4.74 | $5.41 | $28.81 |
| Long term investments | ||||
| Property, plant & equipment | $0.14 | $0.23 | $0.3 | $0.18 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.69 | $0.42 | $0.18 | |
| Total investments | ||||
| Total assets | $2.77 | $5.43 | $5.83 | $28.99 |
| Current liabilities | ||||
| Accounts payable | $2.18 | $2.2 | $4.75 | $3.78 |
| Deferred revenue | $0.02 | $0.17 | $0.52 | |
| Short long term debt | $0.07 | $0.05 | $0.1 | |
| Total current liabilities | $3.21 | $5.52 | $8.16 | $6.7 |
| Long term debt | $0.13 | $0.2 | $0.03 | |
| Total noncurrent liabilities | $0.13 | $0.2 | $0.03 | |
| Total debt | $0.2 | $0.26 | $0.13 | |
| Total liabilities | $3.26 | $5.66 | $8.37 | $6.73 |
| Shareholders' equity | ||||
| Retained earnings | -$117.68 | -$110.24 | -$91.41 | -$61.69 |
| Other shareholder equity | ||||
| Total shareholder equity | -$0.23 | -$2.54 | $22.26 | |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.02 | |||
| Cost of revenue | ||||
| Gross Profit | $0.02 | |||
| Operating activities | ||||
| Research & development | $1.73 | $2.17 | $0.64 | |
| Selling, general & administrative | $1.8 | $1.7 | $0.65 | |
| Total operating expenses | $3.17 | $3.53 | $3.87 | $1.3 |
| Operating income | -$3.53 | -$3.87 | -$1.28 | |
| Income from continuing operations | ||||
| EBIT | -$3.51 | $0.37 | -$1.17 | |
| Income tax expense | ||||
| Interest expense | $0.04 | |||
| Net income | ||||
| Net income | -$3.13 | -$3.51 | $0.37 | -$1.17 |
| Income (for common shares) | -$3.51 | $0.37 | -$1.17 | |
| (in millions $) | 30 Oct 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.02 | $0.15 | $0.35 | $0.48 |
| Cost of revenue | ||||
| Gross Profit | $0.15 | $0.35 | $0.48 | |
| Operating activities | ||||
| Research & development | $11.81 | $21.44 | $16.63 | |
| Selling, general & administrative | $7.13 | $8.58 | $8.94 | |
| Total operating expenses | $11.87 | $18.94 | $30.02 | $25.57 |
| Operating income | -$18.79 | -$29.67 | -$25.09 | |
| Income from continuing operations | ||||
| EBIT | -$18.83 | -$29.72 | -$24.98 | |
| Income tax expense | ||||
| Interest expense | $0.08 | |||
| Net income | ||||
| Net income | -$7.44 | -$18.83 | -$29.72 | -$24.98 |
| Income (for common shares) | -$18.83 | -$29.72 | -$24.98 | |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$3.51 | $0.37 | -$1.17 | |
| Operating activities | ||||
| Depreciation | $0.02 | $0.02 | $0.02 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.06 | $0.06 | $0.05 | |
| Total cash flows from operations | -$3.07 | $0.72 | -$3.09 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.01 | -$0.01 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.01 | $0.06 | $3.84 | |
| Net borrowings | ||||
| Total cash flows from financing | $6.49 | $2.85 | $0.04 | $3.84 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$2.12 | -$0.23 | $0.76 | $0.75 |
| (in millions $) | 30 Oct 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$18.83 | -$29.72 | -$24.98 | |
| Operating activities | ||||
| Depreciation | $0.08 | $0.09 | $0.1 | |
| Business acquisitions & disposals | -$0.44 | -$0.9 | ||
| Stock-based compensation | $0.25 | $0.88 | $1.38 | |
| Total cash flows from operations | -$21.34 | -$27.69 | -$22.55 | |
| Investing activities | ||||
| Capital expenditures | -$0 | |||
| Investments | ||||
| Total cash flows from investing | -$0.01 | -$0.44 | -$0.9 | -$0 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $21.01 | $1.84 | $42.85 | |
| Net borrowings | -$0 | -$0.02 | ||
| Total cash flows from financing | $6.49 | $21.01 | $4.01 | $42.83 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$2.12 | -$0.78 | -$24.57 | $20.27 |
News
Fundamentals
| Market cap | $3.18M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 650.28K |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$7.44M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.43 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.23 |
| EPS | -$11.44 |
|---|---|
| ROA | -150.13% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.66 |
| Quick ratio | N/A |